• Doravirine was found to be noninferior to efavirenz, with consistent virologic suppression rates (HIV-1 RNA < 50 copies/mL) across most patient subgroups with the exception of those defined by age

Based on results of DRIVE-AHEAD and the phase III DRIVE-FORWARD trial, the FDA approved doravirine for treatment-naive adults, both as a single agent to be used in combination with other ARVs and as a once-daily, single-tablet regimen coformulated with lamivudine and tenofovir DF^{[FDA Doravirine; FDA DOR/3TC/TDF]}